Silvana Capalbo

Silvana Capalbo

Auto-generated profile, based on publicly available information

Silvana Capalbo

Institute of Hematology, University of Bari, Italy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2004 in Blood
Verified
Journal Article
Closed access
PDF file
SCSilvia Concetta Colucci
Silvia Concetta Colucci
GBGiacomina Brunetti
Giacomina Brunetti
RRRita Rizzi
Rita Rizzi
AZAntonia Zonno
Antonia Zonno
Giorgio MoriGiorgio Mori
Giorgio Mori
Maria GranoMaria Grano
Maria Grano
The development of multiple myeloma (MM) bone disease is mediated by increased number and activity of osteoclasts (OCs). Using an in vitro osteoclastogenesis model consisting of unstimulated and unfractionated peripheral blood mononuclear cells (PBMCs) from patients with MM, we showed that T cells support the formation of OCs with longer survival. Different from T-cell–depleted MM PBMC cultures, exogenous macrophage-colony stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL) were necessary for the formation of OCs; however, they did not exhibit longer survival. We found up-regulated production of RANKL, osteoprotegerin (OPG), and TNF-related apoptosis-inducing ligand (TRAIL) by fresh MM T cells. Despite high OPG levels, the persistence of osteoclastogenesis can be related to the formation of the OPG/TRAIL complex demonstrated by immunoprecipitation experiments and the addition of anti-TRAIL antibody which decreases OC formation. OCs overexpressed TRAIL decoy receptor DcR2 in the presence of MM T cells and death receptor DR4 in T-cell–depleted cultures. In addition, increased Bcl-2/Bax (B-cell lymphoma-2/Bcl2-associated protein X) ratio, following Bcl-2 up-regulation, was detected in OCs generated in the presence of T cells. Our results highlight that MM T cells support OC formation and survival, possibly involving OPG/TRAIL interaction and unbalanced OC expression of TRAIL death and decoy receptors.

1 August 2006 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
Giovanni D'ArenaGiovanni D'Arena
Giovanni D'Arena
LLLuca Laurenti
Luca Laurenti
SCSilvana Capalbo
Silvana Capalbo
ADAlfonso Maria D'ARco
Alfonso Maria D'ARco
RFRosaria De Filippi
Rosaria De Filippi
APAntonio Pinto
Antonio Pinto

31 March 2011 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ALAnnunziata De Luisi
Annunziata De Luisi
AFArianna Ferrucci
Arianna Ferrucci
ACAddolorata M.L. Coluccia
Addolorata M.L. Coluccia
RRRoberto Ria
Roberto Ria
MMMichele Moschetta
Michele Moschetta
AVAngelo VACCA
Angelo VACCA
Purpose: To determine the in vivo and in vitro antiangiogenic power of lenalidomide, a “lead compound” of IMiD immunomodulatory drugs in bone marrow (BM) endothelial cells (EC) of patients with multiple myeloma (MM) in active phase (MMEC). Experimental Design: The antiangiogenic effect in vivo was studied using the chorioallantoic membrane (CAM) assay. Functional studies in vitro (angiogenesis, “wound” healing and chemotaxis, cell viability, adhesion, and apoptosis) were conducted in both primary MMECs and ECs of patients with monoclonal gammopathies (MGUS) of undetermined significance (MGEC) or healthy human umbilical vein endothelial cells (HUVEC). Real-time reverse transcriptase PCR, Western blotting, and differential proteomic analysis were used to correlate morphologic and biological EC features with the lenalidomide effects at the gene and protein levels. Results: Lenalidomide exerted a relevant antiangiogenic effect in vivo at 1.75 μmol/L, a dose reached in interstitial fluids of patients treated with 25 mg/d. In vitro, lenalidomide inhibited angiogenesis and migration of MMECs, but not of MGECs or control HUVECs, and had no effect on MMEC viability, apoptosis, or fibronectin- and vitronectin-mediated adhesion. Lenalidomide-treated MMECs showed changes in VEGF/VEGFR2 signaling pathway and several proteins controlling EC motility, cytoskeleton remodeling, and energy metabolism pathways. Conclusions: This study provides information on the molecular mechanisms associated with the antimigratory and antiangiogenic effects of lenalidomide in primary MMECs, thus giving new avenues for effective endothelium-targeted therapies in MM. Clin Cancer Res; 17(7); 1935–46. ©2011 AACR.

28 March 2007 in European Journal of Haematology
Verified
Journal Article
Closed access
GDGiovanni D’arena
Giovanni D’arena
CCCatello Califano
Catello Califano
MAMario Annunziata
Mario Annunziata
ATALFREDO TARTARONE
ALFREDO TARTARONE
SCSilvana Capalbo
Silvana Capalbo
NCNicola Cascavilla
Nicola Cascavilla

1 August 2000 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
SCSilvana Capalbo
Silvana Capalbo
PTPaolo Trerotoli
Paolo Trerotoli
ACAngela Ciancio
Angela Ciancio
CBCosima Battista
Cosima Battista
GSGabriella Serio
Gabriella Serio
VLVincenzo Liso
Vincenzo Liso

1 August 2013 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
ANA.M. Nosari
A.M. Nosari
MCM. Caira
M. Caira
MPM.L. Pioltelli
M.L. Pioltelli
RFR. Fanci
R. Fanci
ABA. Bonini
A. Bonini
Livio PaganoLivio Pagano
Livio Pagano
The electronic surveillance system Hema e-Chart allowed us to prospectively collect data and to perform an analysis of invasive fungal infections (IFI) diagnosed in febrile patients as well as the procedures allowing their diagnosis and outcome according to the treatment given. Every patient admitted to 26 Italian Haematology Units with a new diagnosis of haematological malignancy and who was a candidate for chemotherapy was consecutively registered between March 2007 and March 2009. In all, 147 haematological patients with mycoses were identified. Yeasts were found in 23 infections; moulds were diagnosed in 17 proven, 35 probable and 72 possible mycoses. Galactomannan (GM) antigen was the most important test to diagnose probable mould infection; it was positive (cut-off >0.5) in 27 (77%) probable and in nine (53%) proven mould infections. Among patients with probable/proven mould infection who received no prophylaxis or non-mould-active prophylaxis with fluconazole, more patients (n = 26, 78.8%) had GM antigen positivity compared with patients (n = 10, 52.6%) given prophylaxis with mould-active drugs (p <0.05). First-line antifungal therapy was effective in 11/23 (48%) yeast infections and in 37/52 (71.2%) proven/probable mould infections. Twenty patients (14%) died within 12 weeks. The fungal attributable mortality was 30.4% and 17.3% in yeast and proven/probable mould infections, respectively. Among risk factors only age was independently associated (p 0.013) with mortality; sex, underlying haematological malignancy, previous prophylaxis and presence of neutropenia at diagnosis were not significant. A diagnosis of mould infection seemed to have a trend for a better outcome than the diagnosis of yeast infection (p 0.064).